| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2015-04-01 | gevokizumab | type 2 diabetes diabetic nephropathy | 2 | Xoma (USA - CA) Servier (France) | Metabolic diseases - Renal diseases - Kidney diseases - Inflammatory diseases |
| 2015-04-01 | three-dimensional kidney tissue | Organovo (USA - CA) | Kidney diseases - Renal diseases | ||
| 2015-04-01 | AllerT | birch pollen allergy | 2 | Anergis (Switzerland) | Allergic diseases - Immunological diseases |
| 2015-03-31 | BTT1023 - recombinant human monoclonal antibody binding to vascular adhesion protein-1 | primary sclerosing cholangitis | 2a | Biotie Therapies (Finland) | Rare diseases - Inflammatory diseases - Hepatic diseases - Liver diseases |
| 2015-03-30 | Evomela™ (Captisol-Enabled Melphalan (CE-Melphalan) HCl for injection (propylene glycol-free) | multiple myeloma | Spectrum Pharmaceuticals (USA - NV) | Cancer - Oncology | |
| 2015-03-30 | LY3023414 | prostate cancer | 2 | Eli Lilly (USA - IN) | Cancer - Oncology |
| 2015-03-30 | masitinib | head and neck squamous cell carcinoma | 2 | AB Science (France) | Cancer - Oncology |
| 2015-03-30 | SYN-004 | prevention of Clostridium difficile infections |
2a | Synthetic Biologics (USA - MD) | Infectious diseases |
| 2015-03-30 | Infacort® (hydrocortisone oral granules) | pediatric adrenal insufficiency |
3 | Diurnal Limited (UK) | Rare diseases - Endocrine diseases - Hormonal diseases |
| 2015-03-30 | CF101 (IB-MECA (methyl 1-[N6-(3-iodobenzyl)-adenin-9-yl]-b-D-ribofuronamide) | psoriasis |
2-3 | Can-Fite BioPharma (Israel) | Autoimmune diseases - Dermatological diseases |
| 2015-03-28 | selinexor (KPT-330 - (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N'-(pyrazin-2-yl)acrylohydrazide) | multiple myeloma | 2 | Karyopharm Therapeutics (USA - MA) | Cancer - Oncology |
| 2015-03-27 | masitinib | refractory peripheral T-cell lymphoma | 3 | AB Science (France) | Cancer - Oncology |
| 2015-03-27 | Retacrit™, European biosimilar epoetin | chemotherapy-induced anemia | post-marketing | Hospira (USA - IL) | Cancer - Oncology |
| 2015-03-27 | LiquiTime® Guaifenesin | 1 | Flamel Technologies (France) | ||
| 2015-03-26 | BG Medicine (USA - MA) Abbott (USA - IL), AbbVie (USA - IL), AstraZeneca (UK) Merck&Co (USA - NJ) Philips (The Netherlands) Takeda Pharmaceutical (Japan) | Cardiovascular diseases | |||
| 2015-03-26 | agenmestencel-T (genetically-modified mesenchymal stromal cells (MSCs) | advanced adenocarcinoma of the gastro-intestinal tract | 2 | apceth (Germany) | Cancer - Oncology |
| 2015-03-25 | AZP2006 - N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine disulphate salt | progressive supranuclear palsy, Alzheimer disease | 1 | Alzprotect (France) | Rare diseases - Neurodegenerative diseases |
| 2015-03-25 | FIAsp (faster-acting formulation of insulin aspart NovoRapid®) (NN1218) | type 1 and type 2 diabetes | 3 | Novo Nordisk (Denmark) | Metabolic diseases |
| 2015-03-25 | Gazyva®/Gazyvaro® (obinutuzumab) | refractory indolent non-Hodgkin’s lymphoma |
3 | Roche (Switzerland) | Cancer - Oncology |
| 2015-03-25 | MACI™ (Matrix applied characterised autologous cultured chondrocytes) | cartilage defects of the knee | 3 | Vericel Corporation (formerly Aastrom Biosciences) (USA - MI) | Rheumatic diseases |
